Abstract:Abstract: The tumor suppressor protein p53, a transcription factor playing a key role in cancer prevention, interacts with DNA as its primary means of determining cell fate in the event of DNA damage. When it becomes mutated, it opens damaged cells to the possibility of reproducing unchecked, which can lead to formation of cancerous tumors. Despite its critical role, therapies at the molecular level to restore p53 native function remain elusive, due to its complex nature. Nevertheless, considerable information has been amassed, and new means of investigating the problem have become available. Objectives: We consider structural, biophysical, and bioinformatic insights and their implications for the role of direct and indirect readout and how they contribute to binding site recognition, particularly those of low consensus. We then pivot to consider advances in computational approaches to drug discovery. Materials and methods: We have conducted a review of recent literature pertinent to the p53 protein. Results: Considerable literature corroborates the idea that p53 is a complex allosteric protein that discriminates its binding sites not only via consensus sequence through direct H-bond contacts, but also a complex combination of factors involving the flexibility of the binding site. New computational methods have emerged capable of capturing such information, which can then be utilized as input to machine learning algorithms towards the goal of more intelligent and efficient de novo allosteric drug design. Conclusions: Recent improvements in machine learning coupled with graph theory and sector analysis hold promise for advances to more intelligently design allosteric effectors that may be able to restore native p53-DNA binding activity to mutant proteins. Clinical relevance: The ideas brought to light by this review constitute a significant advance that can be applied to ongoing biophysical studies of drugs for p53, paving the way for the continued development of new methodologies for allosteric drugs. Our discoveries hold promise to provide molecular therapeutics which restore p53 native activity, thereby offering new insights for cancer therapies. Graphical abstract: Structural representation of the p53 DBD (PDBID 1TUP). DNA consensus sequence is shown in gray, and the protein is shown in blue. Red beads indicate hotspot residue mutations, green beads represent DNA interacting residues, and yellow beads represent both.

Role of protein-protein interactions in allosteric drug design for DNA methyltransferases

Insights into Conformational Dynamics and Allostery in DNMT1-H3Ub/USP7 Interactions

Both intra and inter-domain interactions define the intrinsic dynamics and allosteric mechanism in DNMT1s

DNA Methyltransferases: Emerging Targets for the Discovery of Inhibitors As Potent Anticancer Drugs

Computer-aided drug design to discover DNMT inhibitors from phytochemicals

Insight into the Selective Binding Mechanism of DNMT1 and DNMT3A Inhibitors: a Molecular Simulation Study.

Deciphering the role of dimer interface in intrinsic dynamics and allosteric pathways underlying the functional transformation of DNMT3A

A Computational Approach for the Discovery of Novel DNA Methyltransferase Inhibitors

Detection of Multiple Network-Based Allosteric Interactions Between Peptides and Arrays of DNA Binding Sites.

Fragment-based discovery of new potential DNMT1 inhibitors integrating multiple pharmacophore modeling, 3D-QSAR, virtual screening, molecular docking, ADME, and molecular dynamics simulation approaches

DNA methyltransferase inhibitors: an updated patent review (2012-2015)

Discovery of novel non-nucleoside inhibitors with high potency and selectivity for DNA methyltransferase 3A

Natural bioactive compounds targeting DNA methyltransferase enzymes in cancer: Mechanisms insights and efficiencies

Identifying Novel Selective Non-Nucleoside DNA Methyltransferase 1 Inhibitors Through Docking-Based Virtual Screening.

An Ultra-Sensitive CRISPR-Cas12a and Aptamer-Based Biosensor Utilizing Entropy-driven Catalytic DNA Networks for Precise Detection of DNA Methyltransferase 1

Navigating the complexity of p53-DNA binding: implications for cancer therapy

Probes and Targets of DNA Methylation and Demethylation in Drug Development

Recent Advance in Nucleic Acid Amplification-Integrated Methods for DNA Methyltransferase Assay

Unveiling the methyl transfer mechanisms in the epigenetic machinery DNMT3A-3 L: A comprehensive study integrating assembly dynamics with catalytic reactions

Emerging Roles of Allosteric Modulators in the Regulation of Protein‐protein Interactions (ppis): A New Paradigm for PPI Drug Discovery

Non-nucleoside inhibitors of DNMT1 and DNMT3 for targeted cancer therapy